Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.
企業コードTBPH
会社名Theravance Biopharma Inc
上場日May 16, 2014
最高経営責任者「CEO」Mr. Rick E. Winningham
従業員数97
証券種類Ordinary Share
決算期末May 16
本社所在地Ugland House, South Church Street
都市GEORGE TOWN
証券取引所NASDAQ Global Market Consolidated
国Cayman Islands
郵便番号KY1-1104
電話番号16508086000
ウェブサイトhttps://www.theravance.com/
企業コードTBPH
上場日May 16, 2014
最高経営責任者「CEO」Mr. Rick E. Winningham
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし